| ￥3000 | |
| Z05977-100 | |
|
|
|
|
|
|
|
|
|
| Species | Monkeypox virus | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | E.coli | ||||
| Theoretical Molecular Weight | 18.89 kDa | ||||
| Apparent Molecular Weight | The protein has a predicted MW of 18.89 kDa same as Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of L1R, His, Monkeypox virus is greater than 95% as determined by SEC-HPLC. »
L1R, His, Monkeypox virus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | L1R, a myristylated late gene product of vaccinia virus, is essential for formation of infectious intracellular mature virions (IMV). In its absence, only viral particles arrested at an immature stage are detected and no infectious progeny virus is produced. |
| Synonyms | OPG100; MPXV083 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
